Sounds familiar ?, page-2

https://raceoncology.com/category/media-release/page/8/?section=3&sl-year=2018

From 2018 - Race Oncology is pleased to announce the appointment of US-based Dr John Cullity as a non-executive director for Race Oncology. Dr Cullity has previously held senior executive roles with Sanofi-Aventis and ...

https://*********.com.au/race-oncology-agreement-pursue-bisantrene-cancer-drug-licensing/

Looks like the Sanofi connection is probably null and void (but it resulted in JC's 8m (cheap) shares).

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.^[2]

So JC must have worked with Sanofi-Aventus between 2004 and 2011, using that association in his CV for the 2018 RAC appointment.